Brain natriuretic peptide

From Self-sufficiency
Jump to: navigation, search
edit
Natriuretic peptide precursor B
Identifiers
SymbolsNPPB; BNP
External IDsOMIM600295 HomoloGene81698 GeneCards: NPPB Gene
RNA expression pattern
250px
More reference expression data
Orthologs
SpeciesHumanMouse
Entrez4879n/a
EnsemblENSG00000120937n/a
UniProtP16860n/a
RefSeq (mRNA)NM_002521n/a
RefSeq (protein)NP_002512n/a
Location (UCSC)Chr 1:
11.84 - 11.84 Mb
n/a
PubMed search[1]n/a

Brain natriuretic peptide (BNP), now known as B-type natriuretic peptide (also BNP) or GC-B, is a 32 amino acid polypeptide secreted by the ventricles of the heart in response to excessive stretching of heart muscle cells (cardiomyocytes). BNP is named as such because it was originally identified in extracts of porcine brain, although in humans it is produced mainly in the cardiac ventricles.

BNP is co-secreted along with a 76 amino acid N-terminal fragment (NT-proBNP) which is biologically inactive. BNP binds to and activates the atrial natriuretic factor receptors NPRA, and to a lesser extent NPRB, in a fashion similar to atrial natriuretic peptide (ANP) but with 10-fold lower affinity. The biological half-life of BNP, however, is twice as long as that of ANP, and that of NT-proBNP is even longer, making these peptides better targets than ANP for diagnostic blood testing.

The physiologic actions of BNP are similar to ANP and include decrease in systemic vascular resistance and central venous pressure as well as an increase in natriuresis. Thus, the net effect of BNP and ANP is a decrease in blood volume and a decrease in cardiac output.

Clinical significance

Both BNP and NT-proBNP levels in the blood are used for screening, diagnosis of acute congestive heart failure (CHF) and may be useful to establish prognosis in heart failure, as both markers are typically higher in patients with worse outcome.[1] The plasma concentrations of both BNP and NT-proBNP are also typically increased in patients with asymptomatic or symptomatic left ventricular dysfunction.[2] There is no level of BNP that perfectly separates patients with and without heart failure.[3] BNP accurately reflects current ventricular status The half-life of NT-ProBNP is 1 to 2 hours vs. 20 minutes for BNP.

BNP > 100 pg per milliliter

BNP > 50 pg per milliliter

For patients with CHF, BNP values will generally be above 100 pg per milliliter; however, a more conservative interpretation of the BNP is that normal values are less than 50 pg per milliliter in order to achieve adequate sensitivity. There is a diagnostic 'gray area', often defined as between 100 and 500 pg/mL, for which the test is considered inconclusive. Values above 500 pg/mL are generally considered to be positive. This so called gray zone has been addressed in several studies and using clinical history or other available simple tools can help make the diagnosis.[4][5]

Bhalla et al. showed that BNP plays a very important role in prognostication of millions of diabetics.[6] Also BNP has an important role in prognostication of heart surgery patients[7] and in the emergency department.[8] Bhalla et al. showed that combining BNP with other tools like ICG can improve early diagnosis of heart failure and advance prevention strategies.[9][10] Utility of BNP has also been explored in various settings like preeclampsia , ICU and shock and ESRD.[11][12][13]

The effect or race and gender on value of BNP and its utility in that context has been studied extensively.[14][15]

NT-proBNP levels (in pg/mL) by NYHA functional class [16]
NYHA I NYHA II NYHA III NYHA IV
5th Percentile 33 103 126 148
Mean 1015 1666 3029 3465
95th Percentile 3410 6567 10,449 12,188

BNP can be elevated in renal failure[citation needed]BNP is cleared by binding to natriuretic peptide receptors (NPRs) and neutral endopeptidase (NEP) Less than 5% of BNP is cleared renally. NTproBNP is the inactive molecule resulting from cleavage of the prohormone Pro-BNP and is SOLELY reliant on the kidney for excretion. The achilles heel of the NT proBNP molecule is the overlap in kidney disease in the heart failure patient population.[17][18]

The BNP test is used as an aid in the diagnosis and assessment of severity of congestive heart failure (also referred to as heart failure). The BNP test is also used for the risk stratification of patients with acute coronary syndromes.[19][20]

When interpreting an elevated BNP level, it is useful to remember that values may be elevated due to factors other than heart failure. Higher levels are often seen in obese patients and those with renal disease, in the absence of heart failure.[21]

BNP is also one of the reasons why people will feel the need to urinate after getting into the bathtub or pool. The increased pressure on the body drives more fluid back into systemic circulation which in turn leads to a slight increase in preload. The left ventricle, and to a small degree the left atrium, secrete BNP in response. The natriuretic effect of BNP leads to an increase in urine production.[22]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

Further reading

  • Cosson S (2004). "Usefulness of B-type natriuretic peptide (BNP) as a screen for left ventricular abnormalities in diabetes mellitus". Diabetes Metab. 30 (4): 381–6. doi:10.1016/S1262-3636(07)70132-5. PMID 15525883. 
  • Cauliez B, Berthe MC, Lavoinne A (2005). "[Brain natriuretic peptide: physiological, biological and clinical aspects]". Ann. Biol. Clin. (Paris). 63 (1): 15–25. PMID 15689309. 
  • Buchner S, Riegger G, Luchner A (2005). "[Clinical utility of the cardiac markers BNP and NT-proBNP]". Acta Med. Austriaca. 31 (4): 144–51. PMID 15732251. 
  • LaPointe MC (2005). "Molecular regulation of the brain natriuretic peptide gene". Peptides. 26 (6): 944–56. doi:10.1016/j.peptides.2004.08.028. PMID 15911064. 
  • Hoffmann U, Borggrefe M, Brueckmann M (2006). "New horizons: NT-proBNP for risk stratification of patients with shock in the intensive care unit". Critical care (London, England). 10 (2): 134. doi:10.1186/cc4883. PMC 1550883Freely accessible. PMID 16594987. 
  • Suga S, Nakao K, Hosoda K; et al. (1992). "Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide". Endocrinology. 130 (1): 229–39. doi:10.1210/en.130.1.229. PMID 1309330. 
  • Kambayashi Y, Nakao K, Mukoyama M; et al. (1990). "Isolation and sequence determination of human brain natriuretic peptide in human atrium". FEBS Lett. 259 (2): 341–5. doi:10.1016/0014-5793(90)80043-I. PMID 2136732. 
  • Hino J, Tateyama H, Minamino N; et al. (1990). "Isolation and identification of human brain natriuretic peptides in cardiac atrium". Biochem. Biophys. Res. Commun. 167 (2): 693–700. doi:10.1016/0006-291X(90)92081-A. PMID 2138890. 
  • Sudoh T, Maekawa K, Kojima M; et al. (1989). "Cloning and sequence analysis of cDNA encoding a precursor for human brain natriuretic peptide". Biochem. Biophys. Res. Commun. 159 (3): 1427–34. doi:10.1016/0006-291X(89)92269-9. PMID 2522777. 
  • Seilhamer JJ, Arfsten A, Miller JA; et al. (1990). "Human and canine gene homologs of porcine brain natriuretic peptide". Biochem. Biophys. Res. Commun. 165 (2): 650–8. doi:10.1016/S0006-291X(89)80015-4. PMID 2597152. 
  • Arden KC, Viars CS, Weiss S; et al. (1995). "Localization of the human B-type natriuretic peptide precursor (NPPB) gene to chromosome 1p36". Genomics. 26 (2): 385–9. doi:10.1016/0888-7543(95)80225-B. PMID 7601467. 
  • Weir ML, Pang SC, Flynn TG (1993). "Characterization of binding sites in rat for A, B and C-type natriuretic peptides". Regul. Pept. 47 (3): 291–305. doi:10.1016/0167-0115(93)90396-P. PMID 7901875. 
  • Totsune K, Takahashi K, Satoh F; et al. (1996). "Urinary immunoreactive brain natriuretic peptide in patients with renal disease". Regul. Pept. 63 (2-3): 141–7. doi:10.1016/0167-0115(96)00035-3. PMID 8837222. 
  • Totsune K, Takahashi K, Murakami O; et al. (1996). "Immunoreactive brain natriuretic peptide in human adrenal glands and adrenal tumors". Eur. J. Endocrinol. 135 (3): 352–6. doi:10.1530/eje.0.1350352. PMID 8890728. 
  • Matsuo K, Nishikimi T, Yutani C; et al. (1999). "Diagnostic value of plasma levels of brain natriuretic peptide in arrhythmogenic right ventricular dysplasia". Circulation. 98 (22): 2433–40. PMID 9832489. 
  • Wiese S, Breyer T, Dragu A; et al. (2001). "Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length". Circulation. 102 (25): 3074–9. PMID 11120697. 
  • Shimizu H, Masuta K, Aono K; et al. (2002). "Molecular forms of human brain natriuretic peptide in plasma". Clin. Chim. Acta. 316 (1-2): 129–35. doi:10.1016/S0009-8981(01)00745-8. PMID 11750283. 
  • Ogawa K, Oida A, Sugimura H; et al. (2002). "Clinical significance of blood brain natriuretic peptide level measurement in the detection of heart disease in untreated outpatients: comparison of electrocardiography, chest radiography and echocardiography". Circ. J. 66 (2): 122–6. doi:10.1253/circj.66.122. PMID 11999635. 
  • Asakawa H, Fukui T, Tokunaga K, Kawakami F (2002). "Plasma brain natriuretic peptide levels in normotensive Type 2 diabetic patients without cardiac disease and macroalbuminuria". J. Diabetes Complicat. 16 (3): 209–13. doi:10.1016/S1056-8727(01)00173-8. PMID 12015190. 
  • Bordenave L, Georges A, Bareille R; et al. (2003). "Human bone marrow endothelial cells: a new identified source of B-type natriuretic peptide". Peptides. 23 (5): 935–40. doi:10.1016/S0196-9781(02)00004-9. PMID 12084525. 

External links

de:Brain Natriuretic Peptide

dv:ބްރޭން ނެޓްރީޔުރެޓިކް ޕެޕްޓައިޑް fr:Peptide cérébral natriurétique nl:Brain natriuretic peptide ja:脳性ナトリウム利尿ペプチド pl:Mózgowy peptyd natriuretyczny pt:Peptídeo natriurético cerebral

sv:Brain natriuretic peptide
  1. Bhalla V, Willis S, Maisel AS (2004). "B-type natriuretic peptide: the level and the drug--partners in the diagnosis of congestive heart failure". Congest Heart Fail. 10 (1 Suppl 1): 3–27. doi:10.1111/j.1527-5299.2004.03310.x. PMID 14872150. 
  2. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  3. Maisel A, Krishnaswamy P, Nowak R, McCord J, Hollander J, Duc P, Omland T, Storrow A, Abraham W, Wu A, Clopton P, Steg P, Westheim A, Knudsen C, Perez A, Kazanegra R, Herrmann H, McCullough P (2002). "Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure". N Engl J Med. 347 (3): 161–7. doi:10.1056/NEJMoa020233. PMID 12124404. 
  4. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  5. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  6. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  7. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  8. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  9. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  10. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  11. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  12. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  13. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  14. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  15. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  16. "N-terminal pro-BNP". 
  17. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  18. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  19. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  20. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  21. Wang TJ, Larson MG, Levy D; et al. (2004). "Impact of obesity on plasma natriuretic peptide levels". Circulation. 109 (5): 594–600. doi:10.1161/01.CIR.0000112582.16683.EA. PMID 14769680. 
  22. Diagnostic Pearls in Cardiorespiratory Disease. CVMA Yosemite Conference 2010. Bruce Keene, DVM, MSc, DACVIM (Cardiology)